Upadacitinib is now approved for IBD patients unsuitable for TNF blockers after one systemic therapy, broadening treatment options. Clinical trials show upadacitinib's efficacy in achieving remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results